Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Martin Glas, Martin Misch et al.|The Lancet|2019Cited by 581
EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastomaEnrico Franceschi, Peter Hau, Silvia Höfer et al.|The Lancet Oncology|2019Cited by 104
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)Dagmar Beier, Peter Hau, Martin Proescholdt et al.|Neuro-Oncology|2017Cited by 90
Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Niklas Schäfer, Theophilos Tzaridis et al.|The Lancet Oncology|2019Cited by 47
Radiation-induced camptocormia and dropped head syndromeClemens Seidel, Kathrin Hering, Thomas Kuhnt et al.|Strahlentherapie und Onkologie|2015Cited by 22